

CONFIDENTIAL: Study Review Final Report

Principal Investigator:	Department/Division:	
Protocol Number(s):	Source of Funding:	
Protocol Title:		
		☐ Randomized Selection
Date of Review:	Type of Selection:	☐ PI Requested Review
Prepared by:	Questions? Contact:	

It is the responsibility of the Principal Investigator:

- 1. To thoroughly review, assess and respond to the findings in this report
- 2. To share and disperse copies of the report with appropriate research staff
- 3. To address all Required Corrective Actions immediately upon receipt of report
- 4. To consider all *Recommended Actions* by choosing one of the following:

☑ Accept Action	tion Recommendation deemed useful and action implemented. Explain how.	
☑ Postpone Action	Recommendation deemed useful, but will be implemented later in study or will be applied to future studies. Explain reason for postponement.	
☑ Decline Action	Recommendation deemed impractical or unfeasible for this study as well as future studies. Please provide reason.	
☑ Acknowledge	An observation may be noted in which no follow-up action is necessary. The PI should acknowledge the observation, or provide clarification.	

■ When all required actions are addressed and recommended actions considered, the PI must:

- 1. Complete the attached <u>Principal Investigator Response Form</u>
- 2. Sign and return the complete PI Response Form within 1 month of receipt to:

EQuIP Office 333 Longwood Ave, 4th Floor

■ Once the EQuIP office determines all required and recommended actions have been satisfactorily addressed, the review will be formally closed.

Please note that this report is <u>CONFIDENTIAL</u>. The details specific to this report will not be shared with the IRB or other groups unless otherwise noted in this report. In such events, the study PI will be notified before any information is shared. A copy will be kept in a study specific file in the EQuIP Office and will be available only to the PI, and the EQuIP staff.

EQ	uIP√ at Children's Hospital Boston	Study Re	eview: FINAL REPORT – PI Protocol
I.	Study Review Timeline		
	Initial Meeting		
	Study & Subject Review		
	Final Meeting		
II.	Study Review Summary		overview of areas reviewed
II.	Study Review Summary Areas Reviewed:	Action(s) Required	Action(s) Recommended
II.		Action(s) Required	Action(s) Recommended
II.	Areas Reviewed:	Action(s) Required	
II.	Areas Reviewed: Regulatory Documentation	Action(s) Required	
II.	Areas Reviewed: Regulatory Documentation CCI Review and Documentation	Action(s) Required	
II.	Areas Reviewed: Regulatory Documentation CCI Review and Documentation Informed Consent Process & Documentation	Action(s) Required	
II.	Areas Reviewed: Regulatory Documentation CCI Review and Documentation Informed Consent Process & Documentation Study Record Keeping & Documentation	Action(s) Required	
II.	Areas Reviewed: Regulatory Documentation CCI Review and Documentation Informed Consent Process & Documentation Study Record Keeping & Documentation Protocol Adherence & Deviation Reporting	Action(s) Required	

III. Notable Best Practices

overview of study strengths

Part A. Required Corrective Actions

A1. Category/Area	
Observation	
Required Action	
Reason	
A2. Category/Area	
Observation	
Required Action	
Reason	
A3. Category/Area	
Observation	
Required Action	
Reason	
A4. Category/Area	
Observation	
Required Action	
Reason	

Part A. Required Corrective Actions

A5.	Category/Area
	Observation
	Required Action
	Reason
1.0	Catagory/Auga
A0.	Category/Area
	Observation
	Required Action
	Reason
Δ7	Category/Area
117.	Observation
	Required Action
	Reason
	Reason
A8.	Category/Area
	Observation
	Required Action
	Reason

Part A. Required Corrective Actions

A9.	Category/Area
	Observation
	Required Action
	Reason
A10	. Category/Area
	Observation
	Required Action
	Reason
A11	. Category/Area
	Observation
	Required Action
	Reason
A 10	Catanani
AIZ	2. Category/Area
	Observation
	Required Action
	Reason

Part B. Recommended Actions

R1	Category/Area
ы.	Observation Observation
	Recommendation
	Reason
	Reason
B2.	Category/Area
	Observation
	Recommendation
	Reason
B3.	Category/Area
	Observation
	Recommendation
	Reason
D.1	G
В4.	Category/Area
	Observation
	Recommendation
	Reason
P 5	Category/Area
DS.	Observation
	Recommendation
	Reason
B6.	Category/Area
DU.	Observation
	Recommendation
	Reason

Best Practices

The following are some best practices that the EQuIP office encourages all research teams to implement. Please review the practices outlined below and the referenced guidance documents/policy. If these practices would benefit the research project and team, please implement as appropriate.

	The <u>Staff Signature Log</u> lists approved staff, with their original signatures, and the timeframe that the staff was on study.
Staff Signature Log	Reference EQuIP Tools & Templates: • Staff Signature Log Guidance • Staff Signature Log The Poles & Regneralibilities Log outlines staff roles and regnerabilities.
	The <u>Roles & Responsibilities Log</u> outlines staff roles and responsibilities, including time on the study and which tasks have been delegated to the team member.
Roles & Responsibilities Log	Reference EQuIP Tools & Templates: • EQuIP Roles & Responsibilities Log Guidance • Roles and Responsibilities Log v.1 • Roles and Responsibilities Log v.2
	The <u>Training Documentation Log</u> serves to provide documentation that adequate training of the research staff has been conducted.
Training Log	Reference EQuIP Tools & Templates: • EQuIP Training Log Guidance • Training Log v.1 • Training Log v.2 • FDA Guidance: Protecting the Rights, Safety, and Welfare of Study Subjects - Supervisory Responsibilities of Investigators
	The Remuneration Log and Receipts provide documentation of remuneration obtained by study staff and distributed to research subjects.
Remuneration Log	Reference EQuIP Tools & Templates: • Remuneration Log • Remuneration Receipts • CCI Policy "Providing Remuneration to Research Subjects"
Informed Consent Form	Ensure all subjects receive a <i>copy of the signed</i> informed consent form.
	Ensure the subject/parent dates their own signature on the consent form. Do not date the signature of the subject/parent.
	The consent process, including any questions the families had and the date that consent was obtained, should be documented in the study documents.
	If a subject/parent signs the consent the same day study participation begins, there must be documentation to clarify that the consent was obtained <i>prior</i> to any study activity.
	Reference:
	 FDA Information Sheet: A Guide to Informed Consent CCI Policy: Documentation of Informed Consent/Parental Permission/Assent

Just to Note

Scientific Review	The summaries of each Department/Division's scientific review process as well as a list their authorized signors can be found on the CCI website, under <i>Scientific Review</i> .
	* Please note: as of June 1, 2005, the CCI will return any new protocol application that do not include documentation of the scientific review, at minimum, the scientific reviewer notes and related correspondence must be included.
Continuing Review Reminder Notices & Amendment Summaries	Prior to each upcoming continuing review (protocol expiration), the CCI/IRB sends out 3 reminder notices, starting approximately 2.5 months before the protocol expiration date. Attached to each reminder notice, is an amendment summary for the protocol. Please ensure the information is correct, and submit back to the CCI/IRB with the application submission.
Outside Monitoring	Please note that for all research studies, any copies of outside monitoring reports, Data Safety Monitoring Reports, FDA Annual (or other) reports, and similar reports should be submitted to the IRB/CCI for their files.
Filing Study Documents	CH/CCI policy now requires investigators to specify in the protocol application and informed consent where each specific document will be filed and who will have access to these documents during and after the study. Guidance is provided on the CCI website in the "Storage of Research Data and Informed Consent Documents" policy.
Translation of Informed Consent Documents	The CCI has funds set aside to assist PIs with the translation of consent forms through interpreter services. To request that a consent form be translated, complete the form "Request for Translation of Research Informed Consent Documents" and submit to the CCI.
CCI Reviewer Worksheets Available	The <u>CCI Reviewer Worksheets</u> that the CCI members use to review new submissions, continuing reviews and amendments are available for the CHB research community to review and use to help prepare their submissions.
Registration of Clinical Trials	Is your clinical trial registered with an ICMJE approved registry?
	In September 2004, the International Committee of Medical Journal Editors (ICMJE) published a statement saying that they would only publish clinical trials that were registered on a publicly accessible registry. Currently, www.clinicaltrials.gov which is operated by the National Library of Medicine (NLM), is the only registry that meets the required elements of registration.
	Please see the <u>CCI Website for more information</u>
Laptop Encryption Policy	As of October 1, 2008, CHB employees and associated personnel that use a laptop for Children's related work or research are required to install encryption software. You may contact the ISD/Help desk or install the software yourself. Go to http://ehelp.tch.harvard.edu/Encryption.html and follow the instructions.